Curated News
By: NewsRamp Editorial Staff
September 17, 2024
Clene (NASDAQ: CLNN) to Meet with FDA to Discuss CNM-Au8 for ALS Treatment
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Clene (NASDAQ: CLNN) will be meeting with the FDA to discuss the development of CNM-Au8 for the treatment of ALS, giving the company a potential advantage in the neurodegenerative disease market.
- Clene Inc. is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, using CNM-Au8 as an investigational therapy.
- Clene's development of CNM-Au8 for the treatment of ALS has the potential to make the world a better place by improving the survival and function of central nervous system cells.
- Clene's CNM-Au8 may be a groundbreaking therapy for improving mitochondrial function and reducing oxidative stress in the treatment of neurodegenerative diseases.
Impact - Why it Matters
This news matters as it highlights Clene's efforts to develop a potential treatment for ALS, a devastating neurodegenerative disease. The meeting with the FDA signifies a crucial step in the development process, and if successful, CNM-Au8 could offer hope to ALS patients and their families.
Summary
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, is set to meet with the FDA to discuss the development of its proprietary CNM-Au8 for the treatment of ALS. The meeting, scheduled before the end of November 2024, will include key FDA representatives and opinion leaders in the ALS space.
Clene Inc. is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS, Parkinson’s disease, and multiple sclerosis. CNM-Au8 is an investigational therapy that targets mitochondrial function and the NAD pathway while reducing oxidative stress.
For more information, please visit www.Clene.com.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene (NASDAQ: CLNN) to Meet with FDA to Discuss CNM-Au8 for ALS Treatment
